Abivax in the news

Two Seas Capital LP acquired a significant new position in Abivax, which is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory and immune-mediated diseases.

Abivax shares fell 2.30% in Paris, with trading volume representing 0.12% of its capitalization.

Abivax's stock fell below its support level, showing a 2.24% decrease, with a significant monthly drop despite reduced short selling pressure.

Abivax stock significantly declined, breaking support, trading below key moving averages, and experiencing continued downward pressure despite reduced short selling.

Cedar Grove Capital Management discussed Abivax, a French biotech company developing treatments for inflammatory bowel diseases, highlighting its de-risked drug obefazimod despite recent stock decline.

Abivax's stock declined due to profit-taking and a more conservative outlook on its regulatory timeline for obefazimod, its lead asset for ulcerative colitis, despite a strong cash position and ongoing development progress.

Abivax shares dropped 3.11% to 80.900 ‰ on the Paris Stock Exchange, with 99,146 shares traded.

ABIVAX Société Anonyme is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases, with its lead drug candidate obefazimod in advanced clinical trials.

The Goldman Sachs Group, Inc. increased its indirect ownership in Abivax to 5.55% of the capital and 5.47% of voting rights as of September 28, 2026, through an off-market share acquisition.

Bank of America Corporation increased its stake in Abivax to over 5% of the capital and voting rights.

Abivax will present seven abstracts on its drug candidate obefazimod for ulcerative colitis at UEG Week 2026, showcasing data from phase 2 and 3 trials and preclinical research.

Abivax stock declined amid broader market tensions and technical resistance, despite upcoming presentations for its drug obefazimod and a reduction in short positions.

Seven scientific abstracts on obefazimod, Abivax's lead drug candidate for ulcerative colitis, will be presented at the United European Gastroenterology Week 2026.

Abivax will present seven abstracts on its drug candidate obefazimod at the UEG Week 2026 in Barcelona, detailing clinical trial results and preclinical research.

Abivax's stock fell 12.9% in a month despite news of obefazimod presentations at a medical conference, with short positions decreasing but still remaining substantial.

Abivax stock fell 5.1% with reduced trading volume, reported mixed quarterly earnings, and maintains a 'Moderate Buy' analyst consensus despite some downgrades.

Abivax's stock rebounded intraday, making it a top gainer in the SBF 120, despite a recent monthly decline, while short positions decreased, and the company reported higher losses and R&D expenses in preparation for a regulatory filing.

Abivax will present obefazimod data at UEG Week 2026, including Phase 3 ABTECT results for ulcerative colitis and long-term Phase 2 data.

Abivax will present comprehensive data on obefazimod's efficacy in chronic inflammatory bowel diseases at the 2026 UEG Week.

Abivax will present new obefazimod data for ulcerative colitis at United European Gastroenterology Week in October 2026, including long-term Phase 2 and Phase 3 trial results.